Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the disease

Prostate Cancer and Prostatic Diseases volume 8, pages 54–59 (2005)Cite this article

Abstract

Objectives: To determine whether COX-2, bcl-2 and neoangiogenesis are related to human prostate cancer relapse after definitive surgical treatment and progression toward androgen independence and to evaluate the association between the patterns of these tumoral biomarkers and other standard clinico-pathological parameters (such as Gleason score, PSA, TNM stage).

Materials and Methods: We retrospectively analyzed the records on 126 prostate cancer samples from patients treated at our University Hospital from 1995 to 2002. The 72 patients with clinically localized disease (group 1) had undergone radical prostatectomy. Another 54 patients (group 2) had metastatic androgen-independent disease. Archived material relating to the subjects was then immunostained for bcl-2, COX-2 and CD-31, using an anti-bcl-2 monoclonal primary antibody, an anti-COX-2 polyclonal rabbit antibody and an anti-CD-31 monoclonal mouse antibody to evaluate neoangiogenesis (MVD, microvessel density).

Results: We found that bcl-2, COX-2 and MVD expression increased from group 1 to group 2. The intergroup difference was significant only for high MVD (P<0.05). On the other hand, high MVD, high bcl-2 and high COX-2 expression was correlated with a higher PSA level (P<0.01), whereas only a high MVD was also related with Gleason score (P<0.05). We used univariate analysis to evaluate the prognostic impact of biologic and clinico-pathologic parameters on the disease-free-survival of 72 patients treated by radical prostatectomy. A total of 30 patients (41.6%) experienced biochemical relapse; bcl-2, COX-2 and MVD significantly correlated with disease relapse in these patients. In fact, we observed disease relapse in 24/45 (53%) with high bcl-2 expression, in 15/21 (71%) with a high MVD count and finally, in 30/58 (52%) with high COX-2 expression. Finally, PSA value and Gleason score were the only two biologic markers significantly associated to disease relapse in a multivariate analysis.

Conclusions: Our results strongly support a role for bcl-2, COX-2 and angiogenesis in the development and progression of prostate cancer. Of course, we are aware of the small sample size considered in our study. Further investigations would better clarify the prognostic and therapeutic implications of these findings.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Walsh PC, Partin AW, Epstein JI . Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 1994; 152: 1831.

    Article  CAS  PubMed  Google Scholar 

  2. Crawford ED, Rosenblum M, Ziada AM, Lange PH . Overview: hormone refractory prostate cancer. Urology 2000; 54: 1–7.

    Article  Google Scholar 

  3. Autorino R et al. Role of chemotherapy in hormone refractory prostate cancer. Old issues, recent advances and new perspectives. Urol Int 2003; 70: 1–14.

    Article  CAS  PubMed  Google Scholar 

  4. Barton J, Blackledge G, Wakeling A . Growth factors and their receptors: new targets fro prostate cancer therapy. Urology 2001; (Suppl 58): 114.

  5. Steiner MS . Role of peptide growth factors in the prostate: a review. Urology 1993; 42: 99–110.

    Article  CAS  PubMed  Google Scholar 

  6. Porter AC, Vaillancourt RR . Tyrosine kinase receptor-activated signal trasduction pathways which lead to oncogenesis. Oncogene 1998; 17: 1343.

    Article  CAS  PubMed  Google Scholar 

  7. Di Lorenzo G et al. Expression of epidermal growth factor (EGFR) correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002; 8: 3438–3444.

    CAS  PubMed  Google Scholar 

  8. Tsujimoto Y, Croce CM . Analysis and structure, transcripts and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 1986; 83: 5214–5218.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Reed JC . Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994; 124: 1–6.

    Article  CAS  PubMed  Google Scholar 

  10. Colombel M et al. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone refractory human prostate cancer. Am J Pathol 1993; 143: 380–400.

    Google Scholar 

  11. McDonnell TJ et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992; 52: 6940–6944.

    CAS  PubMed  Google Scholar 

  12. Raffo AJ et al. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995; 55: 4438–4445.

    CAS  PubMed  Google Scholar 

  13. Gleave ME et al. Progression to androgen independence is delayed by adjuvant treatment with antisense bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate model. Clin Cancer Res 1999; 5: 2891–2898.

    CAS  PubMed  Google Scholar 

  14. Leung S et al. Synergistic chemosensitization and inhibition of progression to androgen-independence by antisense bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model. Int J Cancer 2001; 91: 846–850.

    Article  CAS  PubMed  Google Scholar 

  15. Miyake H, Tolcher A, Gleave ME . Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense bcl-2 oligonucleotides. JNCI 2000; 92: 34–41.

    Article  Google Scholar 

  16. Fernandez A et al. Angiogenic potential of prostate carcinoma cells overexpressing bcl-2. JNCI 2001; 93: 208–213.

    Article  CAS  PubMed  Google Scholar 

  17. Liotta LA, Steeg PS, Stevenson WGS . Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64: 327–336.

    Article  CAS  PubMed  Google Scholar 

  18. Folkman J, Shing Y . Angiogenesis. J Biol Chem 1992; 267: 10931–10934.

    CAS  PubMed  Google Scholar 

  19. Weidner N et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J Pathol 1993; 143: 401–409.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Shih SC et al. Molecular profiling of angiogenesis markers. Am J Pathol 2002; 161: 35–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Jackson MW, Bentel JM, Tilley WD . Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol 1997; 157: 2323–2328.

    Article  CAS  PubMed  Google Scholar 

  22. Giri D, Ropiquet F, Ittmann M . FGF is an autocrine and paracrine prostatic growth factor expressed by prostatic stromal cells. J Cell Physiol 1999; 180: 53–60.

    Article  CAS  PubMed  Google Scholar 

  23. Smith WL, DeWitt DL, Garavito RM . Cyclooxygenases: structural, cellular and molecular biology. Annu Rev Biochem 2000; 69: 145–182.

    Article  CAS  PubMed  Google Scholar 

  24. Hussain T, Gupta S, Mukhtar H . Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett 2003; 191: 125–135.

    Article  CAS  PubMed  Google Scholar 

  25. Liu XH et al. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 2000; 164: 820–825.

    Article  CAS  PubMed  Google Scholar 

  26. Tsujii M, DuBois RN . Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493–501.

    Article  CAS  PubMed  Google Scholar 

  27. Gupta S et al. Overexpression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000; 42: 73–78.

    Article  CAS  PubMed  Google Scholar 

  28. Kirschenbaum A et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology 2000; 56: 671–676.

    Article  CAS  PubMed  Google Scholar 

  29. Yoshimura R et al. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 2000; 89: 589–596.

    Article  CAS  PubMed  Google Scholar 

  30. Zha S et al. Cyclooxygenase-2 is up regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 2001; 61: 8617–8623.

    CAS  PubMed  Google Scholar 

  31. Amling CL et al. Defining prostate specific antigen progression after radical prostatectomy. What is the most appropriate cut point? J Urol 2001; 165: 1146–1151.

    Article  CAS  PubMed  Google Scholar 

  32. Kaplan EL, Meier P . Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  33. Mantel N . Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1996; 50: 163–170.

    Google Scholar 

  34. Cox DR . Regression models and life tables. J Roy Statist Soc 1972; 34: 187–220.

    Google Scholar 

  35. Culing Z et al. Expression, structure and function of androgen receptor in advanced prostate cancer. Prostate 1998; 35: 63–70.

    Article  Google Scholar 

  36. Nazareth LV, Weigel NL . Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem 1996; 271: 19900–19907.

    Article  CAS  PubMed  Google Scholar 

  37. Ye D, Mendelsoh J, Fan Z . Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27 and costimulate proliferation of MDA Pca 2a and MDA PCA 2b prostate cancer cells. Clin Cancer Res 1999; 5: 2171–2177.

    CAS  PubMed  Google Scholar 

  38. Jenster G . Ligand-independent activation of the androgen receptor in prostate cancer by growth factors and cytokines. J Pathol 2000; 191: 227–228.

    Article  CAS  PubMed  Google Scholar 

  39. Catz SD, Johnson JL . Bcl-2 in prostate cancer: a minireview. Apoptosis 2003; 8: 29–37.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank the excellent technical assistance of Mr Gaetano Borriello, Antonella Verbeni, Ersilia Cerbone. We are grateful to Jean Gilder (Scientific Communication) for editing the text.

Author information

Authors and Affiliations

  1. Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Università degli Studi di Napoli Federico II, Naples, Italy

    G Di Lorenzo, S De Placido, M De Laurentiis, G Tortora, M De Sio & A R Bianco

  2. Cattedra di Urologia, Seconda Università degli Studi di Napoli, Naples, Italy

    R Autorino & M D'Armiento

  3. Dipartimento di Scienze Biomorfologiche e Funzionali, Università degli Studi di Napoli Federico II, Naples, Italy

    C Mignogna, M D'Armiento, G De Rosa & F P D'Armiento

Authors
  1. G Di Lorenzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S De Placido
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Autorino
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M De Laurentiis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C Mignogna
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M D'Armiento
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G Tortora
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G De Rosa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M D'Armiento
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M De Sio
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. A R Bianco
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. F P D'Armiento
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G Di Lorenzo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Di Lorenzo, G., De Placido, S., Autorino, R. et al. Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the disease. Prostate Cancer Prostatic Dis 8, 54–59 (2005). https://doi.org/10.1038/sj.pcan.4500768

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500768

Keywords

This article is cited by

Search

Advanced search

Quick links